Investor Type | Firm |
Type of Fund | Private Equity Fund |
Industries | BioTech • Oncology |
Stages | Seed, Startup, Early Stage, Expansion, Later Stage, MBO/LBO, Secondary Purchase |
Investing | United States • Japan |
Investment Range | $50,000,000 - $50,000,000 |
Assets Under Management | $100,000,000 |
Quadrant Capital Partners is a private equity fund based in Dallas with expertise in equity investment, specifically catering to commercial property investments and early-stage companies in Canada and the United States. They provide opportunistically priced capital with an emphasis on partnering with experienced operators who possess proven track records, substantial capital at risk, and realistic value creation strategies. Quadrant has a strong reputation for arranging additional capital through co-investment with high net worth individuals, family offices, and institutions for larger investments or programs. Their strategic operations extend to mezzanine and stretch senior financing for a broad range of stabilized and transitional commercial real estate across the United States. The team at Quadrant Capital Partners is led by Michael Young, the founder with a long history in large-scale real estate and corporate finance, boiling down to a wealth of relationships and perspectives on capital flows across the US/Canadian border. Their investment portfolio is diverse, featuring real estate ventures such as multi-state non-performing single family mortgage pools and for-rent portfolio assemblies. On the corporate investment side, they take on key roles like shareholder and director in companies like RailCrew Xpress in Kansas City and Apache Industrial Services in Houston. Quadrant Capital also shows expertise in property tax lien lending, portfolio assembly of mobile home parks, and has a history of sold interests to major players like the Red McCombs Family and institutional investors. The fund has a substantial $100 million in assets under management and demonstrates a commitment to multi-stage investment opportunities including Seed, Startup, Early Stage, Expansion, Later Stage, MBO/LBO, and Secondary Purchase. They are poised to invest with a minimum and maximum investment size of $50 million, heavily targeting the Biotech and Oncology industries. The scope of their services, investments, and advisory provisions demonstrates a well-rounded approach to capital investment and partnership across North America.